Procedure therapy for cancers that express CD40 antigen.

An anti-CD40 antibody or fragment antigen binding thereof for use in a method of treating a human subject for a cancer comprising neoplastic cells expressing CD40 antigen, wherein said method comprises administering to said subject a therapy combination, wherein it said therapy comprises administration of an effective amount of anti-CD40 antibody or fragment antigen binding thereof in combination with interleukin-2 (IL-2) or biologically active variant thereof, in the wherein said anti-CD40 antibody or fragment antigen binding thereof is free of significant agonist activity when bound to CD40 antigen and is selected from the group consisting of: # a) an antibody or fragment antigen binding thereof, that binds to an epitope capable of binding the monoclonal antibody CHIR-5.9 obtainable from the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5542 or the monoclonal antibody CHIR-12.12 obtainable from the hybridoma cell line deposited the ATCC as Patent Deposit No. PTA-5543; # b) an antibody or antigen binding fragment thereof, that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID NO 10 or SEQ ID NO 12; # c) an antibody or antigen binding fragment thereof, that binds to an epitope comprising residues 82-89 of the human CD40 sequence shown in SEQ ID No. 10 or SEQ ID NO: 12 or; and # d) an antibody or fragment antigen binding thereof that competes with the monoclonal antibody CHIR-5.9 obtainable from the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5542 or the monoclonal antibody CHIR -12.12 obtainable from the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5543 in a competitive binding assay.